Castle Biosciences (CSTL) Cash from Financing Activities (2018 - 2026)

Castle Biosciences has reported Cash from Financing Activities for 9 years, with the latest figure at -$886000.0 in Q2 2026.

• Quarterly Cash from Financing Activities fell 977.23% year-over-year to -$886000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$11.4 million (down 90.48% YoY) and the FY2025 annual result came in at -$7.0 million, down 213.37% from the prior year.
• Cash from Financing Activities improved to -$886000.0 in Q2 2026 per CSTL's latest filing, from -$5.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $10.6 million in Q1 2024 and troughed at -$5.4 million in Q4 2024.
• A 5-year average of -$417944.4 and a median of $43500.0 in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities surged 1762.22% in 2024, then slumped 977.23% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$750000.0 in 2022, then sank by 339.6% to -$3.3 million in 2023, then slumped by 63.33% to -$5.4 million in 2024, then advanced by 14.78% to -$4.6 million in 2025, then jumped by 80.69% to -$886000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$886000.0, -$5.0 million, and -$4.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.